PharmaBlock Sciences
PharmaBlock is a publicly listed Chinese CRDMO providing chemistry research, drug substance and drug product CDMO services, and novel building blocks to nearly all top 20 global pharmaceutical companies and hundreds of biotechs across six sites in the US, China, and Switzerland.
- Company typePublic
- Founded2008
- HeadquartersNanjing, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What PharmaBlock Sciences does
PharmaBlock Sciences (Stock code: 300725.SZSE) is a publicly listed Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Nanjing, China. Officially operational since 2008, the company provides integrated chemistry products and services spanning drug discovery, development, and commercial manufacturing for global pharmaceutical and biotech clients. Its service portfolio includes novel building blocks, chemistry research services, drug substance CDMO (API and intermediate manufacturing), and drug product CDMO (oral solid dosage forms). The company has reportedly partnered with nearly all of the top 20 global pharmaceutical companies and maintains relationships with approximately 700 global partners across six sites in the United States, China, and Switzerland, supported by a workforce of approximately 2,600 employees.
The company's competitive positioning is anchored in proprietary low-carbon manufacturing technologies: continuous flow chemistry deployed across more than 1,800 development and commercial projects, micropacked bed hydrogenation reactors achieving hundreds of metric tons per year, photo flow reactors with up to 100 kg/day output, biocatalysis, and electrochemistry. It has also built an integrated peptide synthesis platform combining liquid-phase peptide synthesis (LPPS), continuous-flow LPPS (CFLPPS), and enzyme-assisted peptide synthesis (EAPS), culminating in a new peptide GMP pilot-scale plant at its Zhejiang site (operational June 2026). These capabilities earned back-to-back ACS Green Chemistry Awards in 2023 and 2024 and recognition alongside GSK and Boehringer Ingelheim by the ACS Green Chemistry Institute Pharmaceutical Roundtable.
PharmaBlock generates revenue through a project-based enterprise CRDMO model: clients engage PharmaBlock directly on multi-year contracts for chemistry research services, drug substance manufacturing, and drug product manufacturing, with pricing negotiated on a per-project basis. Revenue streams span fee-for-service CDMO engagements, chemistry research services, and transactional sale of novel building blocks. The company's go-to-market is enterprise field sales targeting top-tier pharmaceutical accounts and biotech programs, supported by a professional B2B presence through its corporate website, LinkedIn, WeChat, and industry events. Recent strategic emphasis is on expanding into new molecular modalities (oligonucleotides, peptides, complex conjugates) via the OPC Division, positioning PharmaBlock to capture growth in next-generation therapeutic categories while leveraging its established low-carbon chemistry platforms.
PharmaBlock Sciences firmographics
Firmographics- Name
- PharmaBlock Sciences
- Legal name
- PharmaBlock USA Inc
- Website
- https://pharmablock.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- PharmaBlock is a publicly listed Chinese CRDMO providing chemistry research, drug substance and drug product CDMO services, and novel building blocks to nearly all top 20 global pharmaceutical companies and hundreds of biotechs across six sites in the US, China, and Switzerland.
- Ownership category
- akta.pro rank
PharmaBlock Sciences industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where PharmaBlock Sciences is headquartered
LocationHeadquarters
- HQ city
- Nanjing
- HQ country
- China
- HQ region
- Asia
Offices6 records
Markets served
PharmaBlock Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- CDMO Services (Drug Substance & Drug Product): Fee-for-service contract development and manufacturing organization model for APIs, intermediates, and oral solid dosage forms. Revenue is project-based, driven by R&D and GMP manufacturing engagements with pharmaceutical and biotech clients.
- Chemistry Research Services: Chemistry research services providing efficient access to in-house building blocks for research needs, supporting drug discovery programs for small molecule and new modality compounds.
- Novel Building Blocks: Sale of novel and diverse building blocks for research needs of small molecule drugs and new modalities, providing a product-based revenue stream alongside service engagements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise CDMO and research service pricing negotiated on a per-project basis. |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
PharmaBlock Sciences product offering
Product offeringCore offering
PharmaBlock operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) for the pharmaceutical industry, providing novel building blocks for drug discovery, chemistry research services, drug substance CDMO (API and intermediate development and GMP manufacturing), drug product CDMO (oral solid dosage forms), new modalities services (oligonucleotides, peptides, complex conjugates), and CMC regulatory services. Revenue is generated through project-based professional services contracts with global pharmaceutical and biotech clients, supplemented by direct sales of novel building blocks.
Product overview
PharmaBlock is a leading CRDMO (Contract Research, Development, and Manufacturing Organization) providing innovative chemistry products and services throughout the pharmaceutical R&D process and commercial manufacturing. The company operates a multi-site network across the USA, China, and Switzerland with approximately 2,600 employees serving almost all top 20 pharmaceutical companies and hundreds of biotech companies globally. Its portfolio includes Novel Building Blocks for drug discovery, Chemistry Research Services, Drug Substance CDMO (API manufacturing), Drug Product manufacturing (oral solid dosages), and Low-carbon Technology platforms. The company has strategic focus on new molecular modalities through its OPC Division (oligonucleotides, peptides, complex conjugates), supported by integrated technology platforms for peptide synthesis (LPPS, CFLPPS, EAPS) and continuous flow chemistry manufacturing. Founded in 2008, PharmaBlock has grown from building block products to become a comprehensive GMP manufacturing service partner.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel Building Blocks
Quantifiable outcome
- Applied continuous flow chemistry technology across more than 1,800 development and commercial projects.
- +4 more outcomes
Companies that use PharmaBlock Sciences
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
PharmaBlock Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
PharmaBlock Sciences partnerships and signals
Strategic signalScale indicators6 records
Recent moves7 records
Expansion highlights5 records
PharmaBlock Sciences competitors and assessment
Company assessmentDirect peers
- Hovione: Hovione is a privately-held global CDMO specializing in small molecule API and particle engineering with strong continuous-manufacturing capabilities, directly comparable to PharmaBlock's drug-substance offering and customer base.
- ChemPartner (Pharmaron): ChemPartner is a China-based CRO/CDMO offering integrated chemistry services and drug substance manufacturing for global biopharma, overlapping with PharmaBlock's research services and small molecule CDMO.
- Carbogen Amcis: Carbogen Amcis is a Switzerland-based API CDMO with strong drug substance development and high-potency capabilities, comparable to PharmaBlock's European footprint and small-molecule CMC focus.
- Divi's Laboratories: Divi's is a large India-headquartered API and intermediates manufacturer serving global generics and innovator pharma, comparable in drug substance scale, route-of-synthesis focus, and cost-driven manufacturing model.
- WuXi STA (WuXi AppTec): WuXi STA is WuXi AppTec's small molecule CDMO arm and the largest China-based competitor to PharmaBlock, offering integrated drug substance and drug product CDMO services with similar flow-chemistry and peptide capabilities across a global site network.
- Asymchem Laboratories: Asymchem is a leading China-headquartered CDMO providing API/intermediate development and manufacturing to global pharma, with comparable flow chemistry and green-chemistry positioning and overlapping top-20 pharma clients.
Broad incumbents
- Catalent (Thermo Fisher Scientific): Catalent, now part of Thermo Fisher, is a global CDMO with leading drug product (oral solids, softgel, sterile) capabilities, directly comparable to PharmaBlock's drug-product CDMO and top-20 pharma client base.
- Lonza Group: Lonza is the world's largest CDMO with broad small molecule, biologics, peptide and cell-and-gene therapy capabilities; a much larger incumbent that competes with PharmaBlock across the integrated DS+DP and peptide CDMO services.
- Siegfried Holding: Siegfried is a Switzerland-based CDMO with API and drug product manufacturing for innovator and generic pharma, comparable to PharmaBlock's drug substance/drug product integrated model and European presence.
Emerging players
- Aurigene Pharmaceutical Services: Aurigene is an India-based emerging CRDMO with growing small molecule API and biologics offerings serving biotech and large pharma, providing meaningful partial overlap with PharmaBlock's chemistry services and new modality expansion.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
PharmaBlock Sciences social profiles
Digital presencePharmaBlock Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmaBlock Sciences leadership team
Management profileNumber of profiles
Profiles2 records
PharmaBlock Sciences subsidiaries and ownership
Company hierarchySubsidiaries4 records
PharmaBlock Sciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmaBlock Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmaBlock Sciences
What does PharmaBlock Sciences do?
PharmaBlock operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) for the pharmaceutical industry, providing novel building blocks for drug discovery, chemistry research services, drug substance CDMO (API and intermediate development and GMP manufacturing), drug product CDMO (oral solid dosage forms), new modalities services (oligonucleotides, peptides, complex conjugates), and CMC regulatory services. Revenue is generated through project-based professional services contracts with global pharmaceutical and biotech clients, supplemented by direct sales of novel building blocks.
Is PharmaBlock Sciences a public or private company?
PharmaBlock Sciences is a public company. It is classified as public and is currently operating.
When was PharmaBlock Sciences founded?
PharmaBlock Sciences was founded in 2008. It employs 1,001 to 5,000 people.
Where is PharmaBlock Sciences based?
PharmaBlock Sciences is headquartered in Nanjing, China, in the Asia region.
How does PharmaBlock Sciences make money?
Three revenue lines are on record. CDMO Services (Drug Substance & Drug Product) is the primary driver. The others are chemistry Research Services and novel Building Blocks.
Who are PharmaBlock Sciences's main competitors?
Direct peers on record are Hovione, ChemPartner (Pharmaron), Carbogen Amcis, Divi's Laboratories, WuXi STA (WuXi AppTec) and Asymchem Laboratories. Broad incumbents are Catalent (Thermo Fisher Scientific), Lonza Group and Siegfried Holding. Aurigene Pharmaceutical Services is listed as an emerging player.
Does PharmaBlock Sciences have an API?
No public API is recorded for PharmaBlock Sciences.
What industry is PharmaBlock Sciences in?
PharmaBlock Sciences's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.